The Dutch research team found that low levels of NGAL in serum and cerebrospinal fluid can be used as potential biomarkers to predict the conversion of mild cognitive impairment to Alzheimer's disease (AD), and affect the pathophysiological process of AD accompanied by depression (28, 29). Here, LCN2 is linked to depressive symptom measurement.